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Influenza virus infection is a significant global health threat. Because of the lack of 
cross-protective universal vaccines, short time window during which antivirals are 
effective and drug resistance, new therapeutic anti-influenza strategies are required. 
Broadly, cross-protective antibodies that target conserved sites in the hemagglutinin 
(HA) stem region have been proposed as therapeutic agents. FI6 is the first proven 
such monoclonal antibody to bind to H1–H16 and is protective in mice and ferrets. 
Multiple studies have shown that Fc-dependent mechanisms are essential for FI6 in vivo 
efficacy. Here, we show that therapeutic administration of FI6 either intravenously or by 
aerosol to pigs did not reduce viral load in nasal swabs or broncho-alveolar lavage, but 
aerosol delivery of FI6 reduced gross pathology significantly. We demonstrate that pig 
Fc receptors do not bind human IgG1 and that FI6 did not mediate antibody-dependent 
cytotoxicity (ADCC) with pig PBMC, confirming that ADCC is an important mechanism 
of protection by anti-stem antibodies in vivo. Enhanced respiratory disease, which has 
been associated with pigs with cross-reactive non-neutralizing anti-HA antibodies, did 
not occur after FI6 administration. Our results also show that in vitro neutralizing antibody 
responses are not a robust correlate of protection for the control of influenza infection 
and pathology in a natural host model.
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inTrODUcTiOn
Influenza virus infection and immunization induce protective antibody responses. A major part 
of the antibody response is directed at the hemagglutinin (HA) glycoprotein. Influenza HA is 
composed of two domains: the immunodominant globular head, which is strain-specific and the 
stalk which is relatively conserved within each subtype. Seasonal immunization induces antibodies 
predominantly against the globular head which neutralizes the immunizing strain very effectively, 
but escape variants rapidly emerge and are responsible for antigenic drift. In the past decades, 
influenza-neutralizing antibodies that target conserved sites in the HA stem of influenza A viruses 
(IAVs) have been described and these show cross-reactivity between group 1 and 2 viruses (1–7). 
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Anti-stem antibodies are less potent at direct viral neutralization 
as compared to anti-head antibodies, but they mediate protec-
tion in vivo through Fc-dependent effector functions, which can 
be assessed in  vitro by measuring antibody-dependent cellular 
cytotoxicity (ADCC), complement-dependent cytotoxiticy, or 
antibody-dependent cellular phagocytosis (ADCP) (4, 8, 9). 
FI6 was the first proven broadly neutralizing antibody to be 
described, capable of recognizing the HAs of all 16 subtypes and 
neutralizing both group 1 and 2 IAVs (4). Passive transfer of FI6 
conferred protection in mice and ferrets. It has been proposed 
that such broadly cross-reactive antibodies might have potential 
as therapeutic agents for treatment of severe influenza and several 
are tested in clinical trials (10, 11).
A potential problem of developing such antibodies as immune 
therapeutics is enhanced respiratory disease and increased patho-
logy, associated with immune complexes of low avidity or non-
neutralizing antibodies. Vaccine-associated enhanced respiratory 
disease (VAERD) has been observed in pigs when heterologous 
IAV infection occurs after immunization with mismatched whole 
inactivated vaccine (12–15). VAERD was associated with the 
presence of high titer cross-reacting non-neutralizing antibodies 
targeting the conserved stem domain at a site adjacent to the 
fusion peptide. In the absence of neutralizing antibodies against 
the globular head of H1N1pdm09, stem antibodies were associ-
ated with increased virus infection of Madin–Darby canine kidney 
(MDCK) cells in vitro and enhanced membrane fusion (16).
As both pigs and humans are readily infected with IAVs of 
similar subtype, the pig is an appropriate model for investigating 
both swine and human disease. Like humans, pigs are outbred, 
and physiologically, anatomically, and immunologically similar 
to humans. The porcine lung also resembles the human in terms 
of its physiology, morphology, and distribution of receptors 
bound by IAV (17, 18). Here, we used the pig influenza model to 
test whether therapeutic administration of FI6 would reduce or 
enhance disease.
MaTerials anD MeThODs
animals and influenza Virus challenge
Animal experiments were approved by the Pirbright Institute eth-
ics committee, according to the UK Animal (Scientific Procedures) 
Act 1986. Five- to six-week-old landrace cross, female pigs were 
obtained from a commercial high health status herd. Pigs were 
screened for absence of IAV infection by matrix (M) gene real-
time quantitative reverse transcriptase polymerase chain reaction 
(qRT-PCR) (19) and antibody-free status was confirmed using 
HA inhibition with 4 swine IAV antigens—pandemic H1N1, 
H1N2, H3N2, and avian-like H1N1. Pigs weighed between 9 and 
12 kg. All pigs were challenged with 1 × 107 plaque forming units 
(PFU) of A/sw/Eng/1353/09 (pdmH1N1) influenza virus strain. 
The pigs were inoculated by the intra-nasal route using a mucosal 
atomization device, MAD300 (Wolfe Tory Medical) with 2 ml of 
virus administered to each nostril. The virus was propagated in 
MDCK cells. The challenged pigs were randomly divided into 
five groups of five animals and received the following antibod-
ies (experimental design in Figure 1A). (1) Control group—no 
treatment; (2) 15 mg/kg of FI6 antibody intravenously (FI6 I.V.) 
in the ear vein at 1 day post infection (dpi); (3) 1.5 mg/ml FI6 
antibody administered by aerosol (FI6 aer) using InnosSpire Mini 
(Philips Respironics http://evergreen-nebulizers.co.uk/respiron-
ics/innospire_mini.html) with Aerogen mesh reservoir with an 
airspeed of 2 L/min at 1 and 2 dpi; (4) 15 mg/kg of EVB114 anti-
body I.V. in the ear vein at 1 dpi; and (5) 1.5 mg/kg of the MPE8 
antibody by aerosol at 1 and 2 dpi as described above. All anti-
bodies were provided by Humabs BioMed. They were produced 
in Chinese hamster ovary cells, affinity-purified using HiTrap 
Protein A columns (GE Healthcare) followed by desalting using 
HiTrap Fast desalting columns (GE Healthcare). The final product 
were sterilized by filtration through 0.22 µm filters and stored at 
+4°C until use. Antibodies were diluted in phosphate buffered 
saline (PBS) to the desired concentration before administration. 
Animals were monitored by observing demeanor, appetite, and 
respiratory signs, such as coughing and sneezing.
gross Pathology and histopathological 
scoring of lung lesions
Animals were humanely killed 4 dpi with an overdose of pento-
barbital sodium anesthetic. At post mortem, the lungs were 
removed and digital photographs taken on the dorsal and ventral 
aspects. Macroscopic pathology scoring was performed blind 
using Nikon-NIS Br software to determine the proportion of the 
total surface area of each lung lobe affected by typical influenza-
like gross lesions. Five lung tissue samples per animal from the 
right lung (2 pieces from apical lobe, 1 from the medial, 1 from 
the diaphragmatic, and 1 from the accessory) were collected into 
10% neutral buffered formalin for routine histological processing 
at the University of Surrey. Formalin fixed tissues were paraffin 
wax-embedded and 4-µm sections were cut and routinely stained 
with hematoxylin and eosin. Histopathological changes in the 
stained lung tissue sections were scored by a veterinary pathologist 
blinded to the treatment group. Lung histopathology was scored 
using five parameters (necrosis of the bronchiolar epithelium, 
airway inflammation, perivascular/bronchiolar cuffing, alveolar 
exudates, and septal inflammation) scored on a five-point scale 
of 0–4 and then summed to give a total slide score ranging from 0 
to 20 and a total animal score from 0 to 100. Scoring criteria were 
based upon a previously published method (20).
Tissue sample Processing
Four nasal swabs (NS) (two per nostril) were taken at 0, 1, 2, 3, and 
4 dpi. The swabs were placed into 2 ml of virus transport medium 
comprising tissue culture medium 199 (Sigma-Aldrich) sup-
plemented with 25 mM 4-(2-hydroxyethyl)-1-piperazineethane-
sulfonic acid (HEPES), 0.035% sodium bicarbonate, 0.5% bovine 
serum albumin, penicillin 100  IU/ml, streptomycin 100 µg/ml, 
and nystatin 0.25 µg/ml, vortexed, centrifuged to remove debris, 
and stored at −80oC for subsequent virus titration. Serum sam-
ples were collected at the start of the study (prior to challenge) 
and at 2 and 4 dpi. For Fc binding and ADCC assays, blood from 
healthy humans and uninfected pigs was used. Heparinized blood 
samples were diluted 1:1 in PBS before density gradient centrifu-
gation. PBMC were harvested from the interface, washed and red 
FigUre 1 | Experimental design and lung pathology. Pigs were infected with A/sw/Eng/1353/09 and received the indicated antibodies either by the intravenous 
route at 1 day post infection (dpi) or by aerosol at 1 and 2 dpi (a). The animals were sacrificed at 4 dpi and lungs scored for appearance of gross (B) and 
histopathologcial lesions (c). Each data point represents an individual within the indicated group and lines represent the mean. * denotes significant difference  
from the control group (P < 0.05). Representative gross pathology of a pig from control group (D) and FI6 aerosol (e).
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blood cells lysed with ammonium chloride lysis buffer, washed 
again, and used in Fc binding and ADCC assays described below. 
Broncho-alveolar lavage (BAL) was collected from the entire left 
lung with 150 ml of virus transport medium (described above). 
BAL samples were centrifuged at 300 × g for 15 min, supernatant 
was removed, aliquoted, and frozen for antibody analysis.
Virus Titration
Viral titers in nasal swabs and BAL were determined by plaque assay 
on MDCK cells. Duplicate samples were 10-fold serially diluted in 
Dulbecco’s modified Eagle’s medium and 100 µl of each dilution 
added to confluent MDCK cells in 12-well tissue culture plates. After 
1 h, the plates were washed and overlayed with 2 ml 1:32% (w/v) 
agarose:medium. Plates were incubated at 37°C for 48 h, plaques 
visualized by staining the monolayer with 0.1% (v/v) crystal violet, 
and enumerated. RNA was extracted using the QIAamp viral RNA 
mini kit (Qiagen) according to the manufacturer’s protocol and 
viral titers in nasal swabs and BAL fluid was also determined by 
qRT-PCR amplification of the M gene using PCR conditions as 
previously described (21). Forward primer sequence AGA TGA 
GTC TTC TAA CCG AGG TCG, reverse primer sequence TGC 
AAA GAC ACT TTC CAG TCT CTG, and probe sequence FAM-
TCA GGC CCC CTC AAA GCC GA-TAMRA.
enzyme-linked immunosorbent  
assay (elisa)
Human IgG1 antibody levels in serum and BAL fluid were deter-
mined by IgG1 Ready-SET-Go! ELISA (Affymetrix, eBioscience) 
4Morgan et al. FI6 in Pigs
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according to the manufacturer’s instructions. After heat inactiva-
tion (56°C for 30  min) samples were diluted 1:40 (serum) and 
1:2 (BAL fluid). Influenza-specific human Ab titers in serum and 
BAL fluid were determined by ELISA as previously described (20) 
with the following modifications. The IgG ELISA was performed 
in 96-well ELISA plates (BD Biosciences) coated with 1 ×  106 
PFU/ml of A/swine/England/1353/09 over night at 4°C. Twofold 
dilutions of BAL fluid samples or serum (heat inactivated for 
30 min at 56°C) were added, starting from 1:2 or 1:10 dilution, 
respectively. Binding of influenza-specific Abs was detected 
using a monoclonal anti-human IgG (hIgG) (Fc) (Biorad) and 
3,3′,5,5′-tetramethylbenzidine (TMB) substrate (BioLegend). 
Optical density (OD) readings were taken at 450 and 570  nm 
(wavelength correction). Ab values were expressed as endpoint 
titers defined as the highest dilution at which the OD was higher 
than twice the background OD.
Fc Binding
To determine if FI6 was able to bind pig Fc receptors FI6, MPE8, 
and serum from influenza negative and immune (14 dpi) animals 
were incubated at 37°C for 1 h with and without influenza virus. 
Human and pig PBMC were added and incubated for a further 
hour at 4°C. Human PBMC were stained with near-infrared 
fixable Live/Dead (Invitrogen) and anti-hIgG AF488 (HP6017, 
Biolegend) for 20  min at 4°C. Pig PBMC were stained with 
near-infrared fixable Live/Dead (Invitrogen), CD3 AF647 (BB23-
8E6-8C8, BD), CD8α Pe (76-2-11, BD) anti-hIgG, or anti-pig IgG 
FITC (BIO-RAD). Samples were run on a BD LSR Fortessa and 
data analyzed using FlowJo (Treestar).
entry Microneutralization assay
Serum and BAL fluid were heat inactivated at 56°C for 30 min, 
serially diluted 1:2 in 50 µl PBS, starting dilution 1:40 for serum 
and 1:4 for BALF, before addition of 50  µl green-fluorescent 
protein (GFP)—H1 virus diluted in virus growth medium (22). 
Following incubation for 2 h at 37°C 3 × 104 indicator MDCK-
sialyltransferase (SIAT1) cells were added in a volume of 100 µl 
virus growth medium without trypsin and incubated overnight 
at 37°C. Plates were fixed using 4% paraformaldehyde and GFP 
fluorescence intensity (FI) was measured at an excitation of 
483 nm and an emission of 515 nm. Serum and BALF from ani-
mals 14 days post influenza challenge and purified FI6 antibody 
were included as positive controls.
aDcc assay
Madin–Darby canine kidney–2,6-sialyltransferase (SIAT1) stably 
transduced with the lentiviral vector pHR-SIN engineered to 
express the full-length open-reading frame of HA from A/Eng/ 
195/2009 were used as target cells for the ADCC assay (22). The 
HA from A/Eng/195/2009 differs by a single exposed residue at 
D222G from the Eng/1353 that was used to challenge the pigs. 
MDCK-HA cells were seeded in round bottom 96-well plates 
and incubated with different dilutions of heat-inactivated serum 
(1:10, 1:20, 1:40, 1:80, or 1:160) or with different amounts of 
antibody (FI6 or MPE8) for 10 min at 37 C. After that freshly 
isolated human or pig PBMCs from healthy donors or animals 
respectively, were added in a 20 to 1 E:T ratio to the 96-well plates 
and incubated for 4 h at 37°C. MDCK-HA and PBMC were cul-
tured in serum-free AIM-V medium (Life Technologies, UK). At 
the end of the incubation period, 100 µl of cell-free supernatant 
was transferred into a flat bottom 96-well plate and the lactate 
dehydrogenase (LDH) release is measured using the Cytotoxicity 
Detection Kit from Roche according to the manufacturer’s 
instructions. The absorbance was measured at 490 and 620 nm in 
a plate reader. When the purified antibodies, MPE8 and FI6, were 
used as the percentage of cytotoxicity on the Y-axis was calculated 
with the formula: [Sample at each immune antibody dilution 
with target cells and PBMC minus control antibody at the same 
dilution with target cells and PBMC] divided by [maximum 
release of target cells and PBMC in the presence of detergent 
minus control target and effector spontaneous release without 
antibody] × 100. In assessing the ADCC activity of serum sam-
ples, the percentage of cytotoxicity was calculated as described 
above, but using the naïve sera (corresponding dilution to sera of 
immunized pigs to calculate the spontaneous release).
statistical analysis
One-way non-parametric ANOVA (Kruskal–Wallis) with Dunn’s 
post-test for multiple comparisons was performed using GraphPad 
Prism 6.
resUlTs
lung Pathology and Viral load after 
antibody administration
In order to determine the therapeutic effect of FI6 antibody in 
the pig influenza model, FI6 was administered I.V. at 15 mg/kg 
1 dpi. The ebola virus-specific antibody, EVB114 was used as a 
control and delivered at the same concentration I.V. (23). We 
also administered FI6 as an aerosol (aer) as this route of delivery 
is highly efficient in targeting the respiratory tract, which is the 
site of entry and infection of IAV (20, 24–28). We administered 
10 times less FI6 by aerosol (1.5 mg/kg) at 1 and 2 dpi. As a con-
trol for the aerosol delivery we used MPE8, which is a broadly 
neutralizing antibody for human respiratory syncytial virus, 
human metapneumovirus, bovine RSV, and pneumonia virus 
of mice but not IAV (29) (Figure  1A). All of the mAbs were 
monoclonal, fully human IgG1. The clinical signs observed were 
mild and none of the pigs developed moderate or severe disease. 
The control group showed the most severe gross and histopathol-
ogy (Figure 1B–E). A reduction in the gross and histopathology 
score was observed in all the mAb-treated groups. However, this 
reduction was statistically significant only in gross pathology for 
the FI6 aer group. Interestingly despite the reduced lung pathol-
ogy, there were no differences in viral load in nasal swabs at 1, 2, 
3, and 4 dpi (Figure 2A) or in the BAL at the time of sacrifice at 
4 dpi (Figure 2B) as determined by plaque forming assays and 
PCR. This is in contrast with previous studies in mice and ferrets, 
where FI6 administration significantly reduced viral load in the 
lungs (4).
These results indicate that administration of therapeutic FI6 
to pigs did not reduce viral load in NS or BAL, but also it did 
FigUre 2 | Viral load in nasal washes and broncho-alveolar lavage (BAL). Pigs were infected with A/sw/Eng/1353/09 and administered the indicated antibodies 
either by the I.V. route (I.V. solid symbols) or by aerosol (aer, hollow symbols). Nasal swabs (NS) were taken at 0, 1, 2, and 3 day post infection (dpi) and pigs 
sacrificed at 4 dpi. Viral titers in the nasal swabs (a) and BAL (B) were determined by plaque forming assay or real-time quantitative reverse transcriptase 
polymerase chain reaction. Each data point represents an individual within the indicated group and bars represent the mean.
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not exacerbate disease as previously shown with anti-stem anti-
body (16). The mAb-treated groups showed reduced pathology, 
although the reduction was significant only for the aerosol FI6 
group. The reduced pathology is also observed using control anti-
bodies, a finding that might be related to the anti-inflammatory 
and immunomodulatory activities of human IgG1 Fc. Indeed, it 
has been shown that the anti-inflammatory activity of human 
intravenous immunoglobulin is dependent on sialylation of the 
N-linked glycan of the IgG1 Fc fragment (30, 31).
influenza Binding and neutralizing activity 
of administered antibodies
Enzyme-linked immunosorbent assay for human IgG1 confirmed 
that all antibodies were delivered successfully, albeit the control 
EVB114 was detected at a lower concentration in the serum 
perhaps due to differences in the catabolic rates of this mAb. The 
mAb concentrations declined at 4 dpi compared to 2 dpi, but were 
still ~107 μg/ml for FI6 and ~45 μg/ml for EVB114 (Figure 3A). 
Aerosol administration of FI6 and MPE8 did not result in detect-
able quantities of mAbs in the serum. However, mAbs were 
detected in BAL, with ~6.5 µg/ml for FI6 and 0.5 µg/ml for MPE8 
measured at 4 dpi, 2 days after the last aerosol administration, 
most likely indicating that the mAbs are catabolized rapidly 
after aerosol delivery (Figure 3A). Furthermore I.V. FI6 delivery 
resulted in the presence of ~0.33 µg/ml in the BAL 4 days after 
the administration of the antibody, approximately 20-fold less as 
compared to the aerosol FI6 group. To further confirm the pres-
ence and specificity of FI6 after delivery, virus-specific ELISA was 
performed with the challenge virus. As expected influenza-specific 
human mAb was detected in serum after FI6 I.V. delivery at both 
2 and 4 dpi, while in BAL a higher titer was seen after aerosol 
(1:84) compared to FI6 I.V. administration (1:24) (Figure 3B).
To determine whether the FI6 in the serum and BAL were 
still able to neutralize the virus, which might explain the lack 
of reduction of viral titer, we performed entry virus neutraliza-
tion (22). The serum from the FI6 I.V. group was neutralizing 
at both 2 and 4 dpi with a mean 50% inhibitory titer of 1:812 at 
2 dpi and 1:448 at 4 dpi (Figures 4A,B), comparable to control 
immune pig serum. In the BAL of the FI6 aerosol group the mean 
50% inhibitory titer was 1:10 at 4 dpi and in the FI6 I.V. group 
1:3.4 (although only 2 out of the 5 animals had positive results) 
(Figures 4A,C). The neutralization values for the BAL were lower 
than a control BAL fluid (1:640) from a pig sacrificed 14 days post 
challenge with the same virus. No neutralization was detected 
in the animals receiving control antibodies or in the untreated 
FigUre 3 | Mucosal and systemic IgG responses following administration of antibodies. Human IgG1 (a) and pdmH1N1-specific IgG (B) titers in serum at 0, 2, and 
4 day post infection (dpi) and in broncho-alveolar lavage at 4 dpi. Note for pdmH1N1-specific antibody in serum—all five pigs had titers of 1:640 at 4 dpi, while two 
animals at 1:1,024, and three at 1:640 at 2 dpi.
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controls. Pre-challenge sera from FI6-treated animals and BAL 
from control animals did not show any neutralizing activity 
(Figure 4D).
Overall these results indicate that the mAbs were successfully 
delivered and retained their influenza binding and neutralizing 
activity as measured in vitro.
Fc Binding and aDcc
As it has been shown convincingly that most broadly neutralizing 
anti-IAV mAbs mediate their in  vivo effect through antibody 
effector functions (4, 9, 32), we next asked whether the FI6 or 
human IgG1 can bind pig FcR and mediate ADCC. Fc binding 
was assessed after pre-incubating the mAbs with pdmH1N1 
virus in order to form immune complexes. As expected human 
lymphocytes bound FI6 with 74% of the lymphocytes stained 
compared to less than 2% for the controls (Figure 5A). In contrast, 
minimal binding of FI6/pdmH1N1 to pig PBMC was detected. 
A more detailed analysis was performed by gating on pig NK cells, 
defined as CD3−CD8+ (Figures 5B,C), which bound immune pig 
serum pre-incubated with pdmH1N1, but bound very little FI6 
(51.8% for immune pig serum versus 2.37% for FI6). Similar 
results were obtained after detection of immune complexes with 
secondary anti-hIgG, indicating that this antibody could bind the 
pig Ig (Figure 5C).
Finally, to determine whether FI6 can mediate ADCC in pigs 
we evaluated killing by LDH release from MDCK cells stably 
transfected with H1 HA. As previously described, FI6 was able to 
mediate ADCC with human PBMC as effector cells (Figure 6), 
but not with pig PBMC. Immune pig serum from influenza 
infected or immunized pigs gave specific killing.
These results suggest that the failure of FI6 to protect against 
influenza infection in pigs is most likely due to the inability of FI6 
to bind pig FcR and mediate ADCC, and possibly other effector 
functions (e.g., ADCP).
FigUre 4 | Entry neutralization activity of serum and broncho-alveolar lavage (BAL) following administration of antibodies. (a) Individual 50% inhibition titers in the 
serum at 0, 2, and 4 day post infection (dpi) and BAL at 4 dpi. (B) Neutralizing antibody response measured in the serum of the pigs following FI6 I.V. administration 
at 2 and 4 dpi. (c) Antibody response in the BAL of animals given FI6 I.V. or by aerosol at 4 dpi. (D) Negative sera from pre-challenge samples and negative BAL 
from control animals are shown alongside positive control. The dashed line represents the 50% inhibition titer and FI the fluorescence intensity of green-fluorescent 
protein. The neutralizing titer of serum and BAL from animals infected with the same A/sw/Eng/1353/09 virus and sacrificed at 14 dpi is shown in red.
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FigUre 5 | FI6 binding to human and pig Fc receptors. Antibody and pdmH1N1 virus were pre-incubated for 1 h at 37°C and then added to either human or pig 
PBMC. (a) Gated on live cells, singlets, and SSCA versus IgG FITC. (B,c) Gated on live cells, singlets, and CD3−CD8α+ IgG FITC.
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FigUre 6 | Antibody-dependent cytotoxicity (ADCC) activity of pig and human PBMC. Madin–Darby canine kidney cells expressing H1 HA were incubated with FI6, 
MPE8, immune, or normal pig sera in the presence of either pig or human PBMC. ADCC was measured in triplicate by lactate dehydrogenase release. FI6 and 
MPE8 mAbs were used at 10 µg/ml (left panel) or at a concentration range from 0.1 to 1,000 ng/ml (right panel). Representative of three experiments.
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Fc Binding sites in human, Mouse,  
and Pig Fcγrs and igg subclasses
The apparent failure of FI6 to interact functionally with pig FcR 
led us to compare the putative binding sites on both the FcγRs 
and the Fc portion of IgG. Importantly, crystallographic analyses 
of hIgG complexed with human FcγRIII and the structure for 
human FcγRI have elucidated the important contact sites for 
this interaction (33–36). On the receptor, the Fc contact sites are 
spread across the second immunoglobulin domain, and most 
notably in the BC, C’E, and FG loops (Figure 7A). Comparison of 
known mouse, human, and pig FcγR sequences revealed species-
specific variation within these regions, and do not immediately 
suggest that mouse FcγRs would have greater affinity for hIgG 
than the pig (Figure 7A). However, it has been shown that human 
IgG1 binds to mouse FcgRIV and effectively induces ADCC and 
ADCP with mouse NK cells, mouse polymorphonuclear leuko-
cytes, and mouse macrophages (37).
Among the hIgG subclasses, hIgG1 and hIgG3 bind most 
strongly to FcγRs; whereas, hIgG2 and hIgG4 bind either poorly 
or not at all (38). Notably on the Fc portion of the antibody, 
the lower hinge region, the hinge-proximal portion of the CH2 
domain, and an N-linked glycosylation site in CH2 are implica- 
ted in Fc binding. In particular, the motif “LLGG” in the lower 
hinge is believed to play a crucial role (33, 39, 40). Indeed, 
mutation of this motif in hIgG1 to either “VLGG” or “LAGG” 
was previously shown to reduce or prevent binding to FcγRI, 
respectively (41). In addition, the mutation of residues, L234 and 
L235 to alanine to generate the so-called LALA mutant abrogates 
binding to all FcR and C1q (42). Conversely, mutation of hIgG2 
from “VAG” to “LLGG” and of hIgG4 from “FLGG” to “LLGG” 
restored FcγRI binding to levels comparable to hIgG1 (41). 
Interestingly, mice have fully conserved this motif in mIgG2a, 
and have similar motifs in mIgG2b and mIgG3 (“LEGG” 
and “ILGG,” respectively) (Figure  7B). Of the porcine IgGs, 
however, pIgG3 is most similar (“VLGA”), whereas the rest of 
the subclasses lack this motif, and are generally more similar 
to hIgG2 in this region. Thus, the presence of the canonical 
(“LLGG”) FcγR binding motif in both human and mouse IgG, 
but not in pig IgG, suggests that porcine FcγRs recognize the Fc 
portion of IgG differently than in humans and mice. Structural 
analysis revealed that the LLGG motif of human IgG1 interacts 
with hydrophobic residues (LVG) in the FG loop of the human 
FcγRIIIB. Similarly, hydrophobic residues are found in human 
FcγRIIIB and mouse FcγRIV (LFG and LIG, respectively). 
Conversely, the pig FcγRIII carries the IIK motif in the FG loop. 
The analysis of the interaction of the Fc of human IgG1 with 
human FcγRIIIB indicates that the presence of a lysin at position 
159, as found in the porcine FcγRIIIB, would clash with L235, 
thus interfering with the favorable interaction of the LLGG motif 
of human IgG1 with the FG loop required for FcγRIII binding 
(Figure 7C). This observation might explain the lack of binding 
of human IgG1 FI6 to pig PBMCs. Of note, the hinge regions of 
all pig IgGs (except for pig IGHG3) are shorter as compared to 
human IgG1, a finding that might suggest a different modality 
of interaction of the pig Fcs with the cognate FG loop of porcine 
FcγRIII.
DiscUssiOn
Our data shows that therapeutic administration of the broadly 
neutralizing FI6 antibody either I.V. or by aerosol to pigs did not 
result in exacerbation of disease. Aerosol delivery of FI6 was the 
only treatment to reduce gross pathology significantly, although 
viral titers in nasals swabs or BAL were unchanged. We further 
demonstrated that the pig Fc receptors do not bind human IgG1 
and that FI6 did not mediate ADCC with pig PBMC, suggesting 
that the pig is an inappropriate model to evaluate human IgG1 
antibodies.
Previous studies have shown that all neutralizing and non-
neutralizing anti-HA (and anti-neuraminidase) mAbs that rec-
ognize a breadth of influenza strains require FcγRs for protection 
in vivo (4, 9, 32), while strain-specific mAbs did not. This suggests 
FigUre 7 | Putative amino acid sequence alignment of FcγR and IgG subclasses. (a) Second IgG domain of human, mouse, and pig Fcγ receptors. (B) Lower 
hinge and CH2 domain of human, mouse, and pig IgG subclasses. Previously reported Fc-FcγR contact sites are shaded. Beta-strands are labeled and shown at 
top. (c) Left. Model of the interaction of the Fc region of human IgG1 (green) with human FcgRIIIb (light blue) (pdb, 1t83). Fc-bound glycans are shown as orange 
spheres. The L234 and L235 Fc residues (purple) and the G159 residue of the FcγRIIIb FG loop are identified. Right. Modeling of the positioning of the porcine K159 
residue in the FG loop and its clash with the Fc residue L235.
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that the in vitro neutralization mechanism of broadly neutralizing 
mAbs such as inhibition of viral fusion or egress, do not dominate 
in vivo at the doses tested. Our results clearly demonstrate, there-
fore, that in vitro neutralizing antibody responses are not a robust 
correlate of protection for the control of influenza virus infection 
and pathology in a natural host model.
There are limited studies describing porcine FcγRs. Although 
there is obvious overall similarity to their human and mouse 
counterparts, some FcR in domestic animals are unusual, perhaps 
most notably bovine Fcγ2R, which although related to other 
mammalian FcγRs, belongs to a novel gene family and porcine 
FcγRIIIA, which associates with a molecule that contains sig-
nificant homology to the cathelin family of antimicrobial proteins 
(43, 44). Furthermore, the conservation of FcγR binding sites in 
human and mouse IgG, but not in pig IgG, is consistent with our 
findings. Clearly differences in interaction with IgG subclasses, 
cell type, and tissue-specific expression, as well as species differ-
ences should be considered when using these models for in vivo 
evaluation of therapeutic mAbs. Substituting the human Fc 
portion of the FI6 antibody with a pig Fc would provide definitive 
proof of the importance of Fc binding and ADCC for therapeutic 
efficacy of FI6.
It is clear that the delivery of FI6 did not cause pathology or 
exacerbation of disease as described by Khurana et al. (16). In 
their study, the pigs were immunized with a whole irradiation 
inactivated, adjuvanted H1N2 (human-like virus), and chal-
lenged with a different pdmH1N109 strain. The authors suggested 
that the vaccine-induced anti-HA stem antibodies facilitated 
a conformational change in HA that enhanced its fusion and 
increased virus entry into cells in vitro. Nevertheless because FI6 
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does not engage FcR-mediated effector mechanisms in pigs, it is 
still possible that these might contribute to VAERD, for example, 
by massive killing of infected cells, leading to inflammation and 
pathology.
In summary, our data show that therapeutic administration of 
FI6 or a control, either I.V. or by aerosol to pigs did not exacerbate 
disease. Aerosol delivery is an effective means of administration 
for therapeutic mAbs in large animals and possibly humans. FI6 
does not bind to pig Fc receptors or mediate ADCC, confirming 
previous evidence that ADCC is an important mechanism for 
protection by anti-stem Ab in vivo.
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